MNPR Stock Summary and Trading Ideas (Monopar Therapeutics | NASDAQ:MNPR)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics trades on the NASDAQ stock market under the symbol MNPR.

As of April 17, 2024, MNPR stock price declined to $0.65 with 143,497 million shares trading.

MNPR has a beta of 1.59, meaning it tends to be more sensitive to market movements. MNPR has a correlation of 0.01 to the broad based SPY ETF.

MNPR has a market cap of $9.74 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MNPR stock traded as high as $6.98 and as low as $.27.

The top ETF exchange traded funds that MNPR belongs to (by Net Assets): VXF.

MNPR stock has underperformed the market in the last year with a return of -48.1%, while SPY returned +23.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MNPR shares. However, MNPR has outperformed the market in the last 3 month and 2 week periods, returning +58.2% and +2.3%, while SPY returned +5.7% and -3.5%, respectively. This indicates MNPR has been having a stronger performance recently.

MNPR support price is $.66 and resistance is $.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNPR stock will trade within this expected range on the day.